DWA
OCUL icon

Dorsey Wright & Associates’s Ocular Therapeutix OCUL Stock Holding History

Dorsey Wright & Associates’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,646
Closed -$34K – 348
2020
Q4 		$34K Buy
1,646
+412
+33% +$6.12K 0.01% 160
2020
Q3 		$9K Sell
1,234
-412
-25% -$3.42K ﹤0.01% 214
2020
Q2 		$14K Hold
1,646
– – ﹤0.01% 187
2020
Q1 		$8K Buy
+1,646
New +$8.13K ﹤0.01% 191

Other funds holding OCUL

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dorsey Wright & Associates's OCUL Position: Q1 2021 in Review

Dorsey Wright & Associates sold out of Ocular Therapeutix (OCUL) in Q1 2021, closing a stake of 1,646 shares — an estimated $34K sold.

Dorsey Wright & Associates first reported a position in OCUL in Q1 2020 and held it in 4 quarters. The position peaked at $34K in Q4 2020. 154 funds tracked by Wall St. Rank hold OCUL as of Q1 2021.

  • Dorsey Wright & Associates reported no remaining Ocular Therapeutix position as of Q1 2021 after selling out during the quarter.
  • Dorsey Wright & Associates sold 1,646 Ocular Therapeutix shares in Q1 2021, an estimated $34K.
  • Dorsey Wright & Associates first reported a position in Ocular Therapeutix in Q1 2020 and held it in 4 quarters.
  • Dorsey Wright & Associates's Ocular Therapeutix position peaked at $34K in Q4 2020.
  • 154 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2021.

Based on Dorsey Wright & Associates's 13F filing for Q1 2021, filed 27 Apr 2021.